5-cyano-2-methoxybenzoic acid chloride | 3433-90-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-cyano-2-methoxybenzoic acid chloride
• 英文别名: 2-methoxy-5-cyanobenzoyl chloride；5-cyano-2-methoxy-benzoyl chloride；5-cyano-2-methoxybenzoyl chloride；5-cyano-2-methoxybenzoylchloride；2-Methoxy-5-cyano-benzoylchlorid
• CAS: 3433-90-7
• 化学式: C₉H₆ClNO₂
• 分子量: 195.605
• InChiKey: BYESISJSHDVTPA-UHFFFAOYSA-N

物化性质

• 熔点：
  117 °C
• 沸点：
  343.2±27.0 °C(Predicted)
• 密度：
  1.32±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  50.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-cyano-2-methoxybenzoic acid chloride 生成 N-{(3E)-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-5-cyano-2-methoxybenzamide
  参考文献：
  名称：

  NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS

  摘要：

  本发明涉及以下式（I）的化合物 其中A和R1如规范中所定义，包括这些化合物的药物组合物，以及使用这些化合物和药物组合物治疗疾病和疾病的方法。

  公开号：

  US20090105306A1
• 作为产物：
  描述：

  5-cyano-2-methoxybenzoic acid 在 N,N-二甲基甲酰胺 草酰氯 作用下， 以 二氯甲烷 为溶剂， 反应 2.7h， 生成 5-cyano-2-methoxybenzoic acid chloride
  参考文献：
  名称：

  BENZAMIDE DERIVATIVE

  摘要：

  公开号：

  EP1698618B1

文献信息

• COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS
  申请人：Carroll William A.

  公开号：US20100249129A1

  公开（公告）日：2010-09-30

  Disclosed herein are compounds of formula (I) wherein Ring A and R 1 are as defined in the specification. Pharmaceutical compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and pharmaceutical compositions are also disclosed.

  本文揭示了以下式(I)的化合物 其中环A和R 1 如规范中所定义。还披露了包含这些化合物的药物组合物，以及使用这些化合物和药物组合物治疗疾病和疾病的方法。
• Disubstituted piperazines
  申请人：Ciba-Geigy Corporation

  公开号：US04804661A1

  公开（公告）日：1989-02-14

  Piperazines of the formula ##STR1## and their salts, in which each of Ar.sub.1 and Ar.sub.2, independently of the other, represents phenyl that is unsubstituted or mono- or di-substituted by C.sub.1 -C.sub.7 -alkyl, C.sub.1 -C.sub.7 -alkoxy, cyano, halogen, trifluoromethyl, amino, C.sub.1 -C.sub.7 -alkylamino, di-C.sub.1 -C.sub.7 -alkylamino and/or by C.sub.1 -C.sub.7 -alkanoylamino, can be used as the active ingredients of medicaments and are manufactured in a manner known per se.

  该公式中的哌嗪类化合物及其盐，其中Ar.sub.1和Ar.sub.2中的每一个，独立于另一个，代表未取代或经C.sub.1-C.sub.7-烷基，C.sub.1-C.sub.7-烷氧基，氰基，卤素，三氟甲基，氨基，C.sub.1-C.sub.7-烷基氨基，二C.sub.1-C.sub.7-烷基氨基和/或C.sub.1-C.sub.7-烷酰氨基取代的苯基，可以作为药物的活性成分，并以已知的方式制造。
• Carboxamides
  申请人：Ciba Geigy Corporation

  公开号：US04559349A1

  公开（公告）日：1985-12-17

  The invention relates especially to pharmaceutical preparations containing N-(piperidinyl-alkyl)-carboxamides of the general formula ##STR1## in which R represents hydroxy, hydroxy etherified by an aliphatic alcohol, or halogen, Ar.sub.1 represents a monocyclic arylene or heteroarylene radical, alk represents an alkylene group that separates the two N atoms by at least two carbon atoms, X represents a free or ketalized carbonyl group, free hydroxymethylene or hydroxymethylene esterified by an organic carboxylic acid, or methylene, and Ar.sub.2 represents a monocyclic aryl or heteroaryl radical, and salts thereof, the use of these compounds of the formula I and salts thereof, novel compounds of the formula I and salts thereof in which R, Ar.sub.1, alk, X and Ar.sub.2 have the meanings given, with the proviso that the grouping R--Ar.sub.1 is other than a radical of the formula ##STR2## in which R.sub.1 is selected from the group consisting of lower alkyl, trifluoromethyl, halogen, lower alkoxy, nitro and cyano and at least one of the radicals R.sub.1 represents halogen or lower alkoxy, n represents an integer from 1 to 3, and Z represents nitro, amino, lower alkylamino, arylamino, aryl-lower alkylamino, (thio-)formylamino, (thio-)lower alkanoylamino, (thio-)aroylamino or aryl-(thio-)lower alkanoylamino, if alk and X have the meanings given and Ar.sub.2 represents unsubstituted phenyl, thienyl or pyridyl or substituted phenyl having one, two or three substituents selected from the group consisting of halogen, lower alkyl, lower alkoxy, trifluoromethyl and amino, and to processes for the manufacture thereof.

  本发明涉及含有通式##STR1##中N-(哌啶基-烷基)-羧酰胺的制药制剂，其中R代表羟基、被脂肪醇醚化的羟基或卤素，Ar.sub.1代表单环芳基或杂环芳基，alk代表通过至少两个碳原子分隔的烷基，X代表自由或缩酮化的羰基、自由的羟亚甲基或被有机羧酸酯化的羟亚甲基，或甲亚甲基，Ar.sub.2代表单环芳基或杂环芳基，以及其盐。本发明还涉及公式I中这些化合物和其盐的用途，以及具有给定含义的R、Ar.sub.1、alk、X和Ar.sub.2的新化合物和其盐，其中R-Ar.sub.1的分组不是公式##STR2##中R.sub.1选自下列组：低烷基、三氟甲基、卤素、低烷氧基、硝基和氰基，至少一个基团R.sub.1代表卤素或低烷氧基，n为1到3的整数，Z代表硝基、氨基、低烷基氨基、芳基氨基、芳基-低烷基氨基、(硫-)甲酰氨基、(硫-)低脂肪酰氨基、(硫-)芳酰氨基或芳基-(硫-)低脂肪酰氨基，如果alk和X具有所述含义，Ar.sub.2代表未取代的苯基、噻吩基或吡啶基或具有一个、两个或三个卤素、低烷基、低烷氧基、三氟甲基和氨基中的一种或几种取代基的取代苯基，以及其制造方法。
• Pharmaceutical Compounds
  申请人：Berdini Valerio

  公开号：US20100004232A1

  公开（公告）日：2010-01-07

  The use of a compound for the manufacture of a medicament for the prophylaxis or treatment of: A. a disease state or condition mediated by a kinase which is BCR-abl, VEGFR, PDGFR, EGFR, Flt3, JAK (e.g. JAK2 or JAK3), C-abl, PDK1, Chk (e.g. Cbk1 or Chk2), FGFR (e.g. FGFR3), Ret, Eph (e.g. EphB2 or EphB4), or Src (e.g. cSrc); or B. a cancer in which the cancer cells thereof contain a drug resistant kinase mutation which is: (a) a threonine gatekeeper mutation; or (b) a drug-resistant gatekeeper mutation; or (c) an imatinib resistant mutation; or (d) a nilotinib resistant mutation; or (e) a dasatinib resistant mutation; or (f) a T670I mutation in KIT; or (g) a T674I mutation in PDGFR; or (h) T790M mutation in EGFR; or (i) a T315I mutation in abl; or C. a cancer which expresses a mutated molecular target which is a mutated form of BCRabl, c-kit, PDGF, EGF receptor or ErbB2; or D. a disease mediated by a kinase containing a mutation in a region of the protein that binds to or interacts with other cancer agents but does not bind to or interact with the compounds of formula (I) or (I′), for example a mutated kinase selected from c-abl, c-kit, PDGFR including PDGFR-beta and PDGFR-alpha, and ErbB family members such as EGFR (ErbB1), HER2 (ErbB2), ErbB3, and ErbB4, members of the Ephrin receptor family including EphA1, EphA2, EphA3, EphA4, EphA5, EphA8, EphA10, EphB1, EphB2, EphB3, EphB5, EphB6, c-Src and kinases of the JAK family such as TYK2; wherein the compound is a compound of the formula (I or I′): or a salt, solvate, tautomer or N-oxide thereof wherein R 0′ , R 1 , R 1′ , R 2′ , R 3′ , R 4′ , A′, X′, E, A and M are as defined in the claims.

  使用该化合物制造药物，用于预防或治疗以下疾病状态或条件：A. 由激酶介导的疾病状态或条件，其中激酶是BCR-abl、VEGFR、PDGFR、EGFR、Flt3、JAK（例如JAK2或JAK3）、C-abl、PDK1、Chk（例如Cbk1或Chk2）、FGFR（例如FGFR3）、Ret、Eph（例如EphB2或EphB4）或Src（例如cSrc）；或B. 癌症，其癌细胞含有耐药激酶突变，该耐药激酶突变是：（a）苏氨酸门卫突变；或（b）耐药门卫突变；或（c）伊马替尼耐药突变；或（d）尼洛替尼耐药突变；或（e）达沙替尼耐药突变；或（f）KIT中的T670I突变；或（g）PDGFR中的T674I突变；或（h）EGFR中的T790M突变；或（i）abl中的T315I突变；或C. 表达突变分子靶点的癌症，该突变分子靶点是BCRabl、c-kit、PDGF、EGF受体或ErbB2的突变形式；或D. 由激酶介导的疾病，其中激酶在与其他癌症药物结合或相互作用的蛋白质区域中具有突变，但不与式（I）或（I'）化合物结合或相互作用，例如选择自c-abl、c-kit、PDGFR（包括PDGFR-beta和PDGFR-alpha）和ErbB家族成员，如EGFR（ErbB1）、HER2（ErbB2）、ErbB3和ErbB4，包括Ephrin受体家族成员，如EphA1、EphA2、EphA3、EphA4、EphA5、EphA8、EphA10、EphB1、EphB2、EphB3、EphB5、EphB6、c-Src和JAK家族的激酶；其中该化合物是式（I或I'）的化合物：或其盐、溶剂合物、互变异构体或N-氧化物，其中R0'、R1、R1'、R2'、R3'、R4'、A'、X'、E、A和M如权利要求所定义。
• Pyrazole Compounds that Modulate the Activity of Cdk, Gsk and Aurora Kinases
  申请人：Berdini Valerio

  公开号：US20080132495A1

  公开（公告）日：2008-06-05

  The invention provides a compound of the formula (I): or a salt, solvate, tautomer or N-oxide thereof, wherein M is selected from a group D1 and a group D2: and R′, E, A and X are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds, processes for making the compounds and the use of the compounds in the prophylaxis or treatment of a disease state mediated by a CDK kinase, GSK-3 kinase or Aurora kinase.

  该发明提供了式(I)的化合物或其盐、溶剂化物、互变异构体或N-氧化物，其中M被选自D1组和D2组：而R′、E、A和X如权利要求所定义。还提供了包含该化合物的药物组合物、制备该化合物的方法以及在预防或治疗由CDK激酶、GSK-3激酶或Aurora激酶介导的疾病状态中使用该化合物的用途。